DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Harbour Investments Inc.

Harbour Investments Inc. increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 8.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,895 shares of the medical device company’s stock after acquiring an additional 1,046 shares during the quarter. Harbour Investments Inc.’s holdings in DexCom were worth $864,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Taylor Frigon Capital Management LLC lifted its position in shares of DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after acquiring an additional 11,075 shares in the last quarter. National Pension Service raised its stake in DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Intact Investment Management Inc. purchased a new position in DexCom in the 3rd quarter valued at $650,000. Waters Parkerson & CO. LLC boosted its stake in DexCom by 4.2% during the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after purchasing an additional 10,892 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after buying an additional 49,076 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $145.00 price target on shares of DexCom in a research note on Tuesday, July 23rd. Robert W. Baird boosted their target price on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. UBS Group reduced their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Sanford C. Bernstein boosted their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Finally, BTIG Research cut their target price on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $75.88 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a 50 day moving average price of $69.89 and a 200 day moving average price of $92.01. The stock has a market capitalization of $29.64 billion, a P/E ratio of 45.36, a PEG ratio of 2.22 and a beta of 1.17.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.